ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine. ACT recently secured a patent on its “embryo-safe” single-blastomere technology and in June of 2010 secured a broad patent for production of RPE cells.
Corporate Governance